No Conclusion Yet On Value Of Imreg-1

It was lmreg Inc., of New Orleans, La., playing David opposite the well-established, well-heeled, well-staffed, pharmaceutical Goliaths last summer. At that time, lmreg was one of the five companies in the race to develop anti-AIDS drugs that had completed FDA clinical trials for its AIDS products—and with nine scientists on board it was by far the smallest firm. (See “A Tiny Biotech Startup Wages War Against AIDS,” The Scientist, August 8, 1988, page 1.) It was a promising start for the company, which was founded by a husband and wife who are both Tulane University professors: But lately all hasn’t been smooth sailing for the drug startup. An FDA meeting on April 7 yielded inconclusive results for Imreg-1,the drug the company hopes to market for patients with AIDS-related complex. After an all-day session, the FDA staff concluded that Imreg-1 was no better...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?